all report title image
  • Published On : Jan 2023
  • Code : CMI5181
  • Industry : Pharmaceutical
  • Pages : 194
  • Formats :

Alzheimer's disease is a neurodegenerative condition that typically develops gradually and gets worse over time. It is a form of dementia that progresses over time, causing a person's capacity for independent functioning to be disrupted by a steady decline in thinking, behavioural, and social abilities. Alzheimer's disease has no known cure, but there are treatments that may slow down the disease's progression as well as medication and non-medication options that could help manage symptoms.

Global Alzheimer’s disease diagnostics and therapeutics market is estimated to be valued at US$ 6,231.1million in 2022 and is expected to exhibit a CAGR of 5.4% during the forecast period (2022-2030).

Figure 1. Global Alzheimer’s disease Diagnostics and Therapeutics Market Share (%), By Product, 2022

Alzheimer’s disease Diagnostics and Therapeutics  | Coherent Market Insights

Global Alzheimer’s disease Diagnostics and Therapeutics Market- Drivers

Increase in the prevalence of Alzheimer’s disease in the old age population is expected to drive the market for the forecast period.

According to Alzheimer's Association, April 2022, an estimated 6.5 million people age 65 and older in 2021 were living with Alzheimer's in the U.S. among which 73% were aged 75 or older.

Key players are focusing on providing new diagnostic tests which will drive the market growth during the forecast period. For instance, Attyloid GmbH, a biotechnology company, offers a biomarker-based laboratory test sFIDA (surface-based fluorescence intensity distribution analysis), for diagnosing Alzheimer’s disease. sFIDA can identify and quantify Aβ oligomers. These small protein aggregates play a significant role in the development and prognosis of Alzheimer’s disease. By sFIDA, differentiation between control samples and AD patient is easily possible.

CMI table icon

Alzheimer’s disease Diagnostics and Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 6,231.1 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 5.4 % 2030 Value Projection: US$ 9,503.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), Diagnostics (Brain Imaging, CSF Test for Alzheimer’s Disease)
Companies covered:

Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.

Growth Drivers:
  • Increase in the prevalence of Alzheimer’s disease
  • Launch of novel diagnostic test
Restraints & Challenges:
  • Uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs

Figure 2. Global Alzheimer’s disease Diagnostics and Therapeutics Market Share (%), by Region, 2022

Alzheimer’s disease Diagnostics and Therapeutics  | Coherent Market Insights

Global Alzheimer’s disease Diagnostics and Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.

The rising cases of COVID-19 are expected to have a short-term negative impact on diagnostic rates of Alzheimer's disease. The short-term effects on the market are less prominent; however, the adverse impacts of COVID-19 on the global economy can have significant effects on the market.

Global Alzheimer’s disease Diagnostics and Therapeutics Market: Key Developments

In October 2021, Salk Institute, a research institute in California, U.S., initiated a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to evaluate its safety in humans.

Moreover, In June, 2021, Biogen, a multinational biotechnology company, and Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., announced a range of programs/initiatives intended to support access for all qualified patients, including traditionally underserved populations

Global Alzheimer’s disease Diagnostics and Therapeutics Market: Restraint

The uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs lead to the availability of limited treatment alternatives. This increases the costs related to research and development. Hence, it is expected to restrain the market growth. For instance, Amgen Inc. and Novartis AG discontinued their Phase 2 clinical trial for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer's disease, in July 2019, due to the lack of desired results.

Global Alzheimer’s disease Diagnostics and Therapeutics Market- Key Players

Major players operating in the global Alzheimer’s disease diagnostics and therapeutics market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.

Alzheimer’s disease is a neurodegenerative disease that usually starts slowly and progressively worsens. It is a progressive form of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. Doctors perform a series of tests to rule out other possible causes of impairment. It can be diagnosed in several different ways. Imaging techniques, such as CT and MRI, are primarily used to rule out other conditions that may cause symptoms similar to Alzheimer's but require different treatment. There's no cure for Alzheimer's disease, but there are treatments that may change disease progression, and drug and non-drug options that may help treat symptoms. Aducanumab is the only disease-modifying medication currently approved to treat Alzheimer's. Medications may temporarily improve or slow progression of symptoms. These treatments can sometimes help people with Alzheimer's disease maximize function and maintain independence for a time. In advanced stages of the disease, complications from severe loss of brain function — such as dehydration, malnutrition or infection — result in death.

Market Dynamics

Increasing use of biomarkers in Alzheimer’s diagnosis and drug development and increasing focus on the development of novel diagnostics & therapeutics due to increase in disease burden is expected to boost the growth of the global Alzheimer’s disease diagnostics and therapeutics market. For instance, in June 2021, the Alzheimer’s Drug Discovery Foundation (ADDF) Diagnostics Accelerator launched four new research investments for the development of digital biomarkers for Alzheimer's diagnosis. Moreover, in August 2022, the Alzheimer's Association announced the launch of Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), a platform to collect long-term clinical and safety data from patients treated with U.S FDA-approved Alzheimer's disease therapies in real world clinical settings. It is the first network developed specifically for FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time.

Key features of the study:

  • This report provides in-depth analysis of the global Alzheimer’s disease diagnostics and therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Alzheimer’s disease diagnostics and therapeutics market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Alzheimer’s disease diagnostics and therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alzheimer’s disease diagnostics and therapeutics market

Detailed Segmentation:

  • Global Alzheimer’s Disease Diagnostics And Therapeutics Market, By Product:
    • Therapeutics
      • Cholinesterase Inhibitors
      • NMDA Receptor Antagonists
      • Others 
    • Diagnostics   
      • Brain Imaging
      • CSF Test for Alzheimer’s Disease
  • Global Alzheimer’s Disease Diagnostics And Therapeutics Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Luye Pharma Group
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Vigil Neuroscience, Inc.
    • Grifols, S.A.
    • AbbVie Inc.
    • Zydus Lifesciences Ltd.
    • Merck KGaA
    • Hoffmann-La Roche Ltd.
    • Novartis AG
    • Johnson & Johnson
    • Eli Lilly and Company
    • Biogen Inc.
    • Siemens Healthcare GmbH
    • Merz Pharma
    • Eisai Co. Ltd.
    • Lupin Limited
    • Teva Pharmaceutical Industries Ltd.
    • Apotex Inc.
    • Corium, Inc.
    • Supernus Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global Alzheimer’s disease diagnostics and therapeutics market size is estimated to be valued at US$ 6,231.1 million in 2022 and is expected to exhibit a CAGR of 5.4% between 2022 and 2030.
Factors such as increase in the prevalence of Alzheimer’s disease and launch of novel diagnostic test are expected to drive the market growth.
Diagnostics is the leading product segment in the market.
The major factors hampering growth of the market include uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs.
Major players operating in the market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo